Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ORAI1 modulators(Ca2+ release activated Ca2+ channel 1 modulators), STIM1 modulators(Stromal interaction molecule 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC23H19N3O4 |
InChIKeyQEGLPUSVIMJFRX-UHFFFAOYSA-N |
CAS Registry2694056-16-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Congenital Structural Myopathy | Preclinical | IT | 01 Sep 2024 | |
Muscular Dystrophy, Duchenne | Preclinical | IT | ChemiCare SrlStartup | 01 Sep 2024 |
Muscular Dystrophy, Duchenne | Preclinical | IT | 01 Sep 2024 |